evrysdi
roche registration gmbh - risdiplam - spier-atrofie, spinale - andere geneesmiddelen voor aandoeningen van het musculo-skeletale systeem - evrysdi is indicated for the treatment of 5q spinal muscular atrophy (sma) in patients with a clinical diagnosis of sma type 1, type 2 or type 3 or with one to four smn2 copies.
sunitinib accord
accord healthcare s.l.u. - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastische middelen - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.
primene 10 % inf. opl. i.v.
baxter sa-nv - cysteïne 1,89 g/1000 ml; taurine 0,6 g/1000 ml; methionine 2,4 g/1000 ml; valine 7,6 g/1000 ml; tryptofaan 2 g/1000 ml; fenylalanine 4,2 g/1000 ml; threonine 3,7 g/1000 ml; isoleucine 6,7 g/1000 ml; glycine 4 g/1000 ml; leucine 10 g/1000 ml; proline 3 g/1000 ml; lysine 11 g/1000 ml; glutaminezuur 10 g/1000 ml; alanine 8 g/1000 ml; asparaginezuur 6 g/1000 ml; serine 4 g/1000 ml; tyrosine 0,45 g/1000 ml; ornithine hydrochloride 3,18 g/1000 ml; arginine 8,4 g/1000 ml; histidine 3,8 g/1000 ml - oplossing voor infusie - combinations
primene 10 % inf. opl. i.v.
baxter sa-nv - cysteïne 1,89 g/1000 ml; taurine 0,6 g/1000 ml; methionine 2,4 g/1000 ml; valine 7,6 g/1000 ml; tryptofaan 2 g/1000 ml; fenylalanine 4,2 g/1000 ml; threonine 3,7 g/1000 ml; isoleucine 6,7 g/1000 ml; glycine 4 g/1000 ml; leucine 10 g/1000 ml; proline 3 g/1000 ml; lysine 11 g/1000 ml; glutaminezuur 10 g/1000 ml; alanine 8 g/1000 ml; asparaginezuur 6 g/1000 ml; serine 4 g/1000 ml; tyrosine 0,45 g/1000 ml; ornithine hydrochloride 3,18 g/1000 ml; arginine 8,4 g/1000 ml; histidine 3,8 g/1000 ml - oplossing voor infusie - combinations
thalidomide lipomed
lipomed gmbh - thalidomide - multiple myeloma - immunosuppressiva - thalidomide lipomed in combination with melphalan and prednisone is indicated as first line treatment of patients with untreated multiple myeloma, aged ≥ 65 years or ineligible for high dose chemotherapy. thalidomide lipomed is prescribed and dispensed in accordance with the thalidomide lipomed pregnancy prevention programme (see section 4.
ztalmy
marinus pharmaceuticals emerald limited - ganaxolone - epileptic syndromes; spasms, infantile - andere anti-epileptica - ztalmy is indicated for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (cdkl5) deficiency disorder (cdd) in patients 2 to 17 years of age. ztalmy may be continued in patients 18 years of age and older.
dextroforme 1 mg/ml siroop
conforma sa-nv - dextromethorfanhydrobromide 1 mg/ml - siroop - 1 mg/ml - dextromethorfanhydrobromide 1 mg/ml - dextromethorphan
aqua cuprozincica conforma 7,65 mg/ml - 25,5 mg/ml cut. opl.
conforma sa-nv - zinksulfaatheptahydraat - eq. zinksulfaat 25 mg/g; kopersulfaat 7,65 mg/ml - oplossing voor cutaan gebruik - 7,65 mg/ml - 25,5 mg/ml - kopersulfaat 7.65 mg/ml; zinksulfaatheptahydraat - antiseptics and disinfectants
codeinesiroop met eucalyptolsmaak conforma 2,67 mg/ml siroop
conforma sa-nv - codeïne 2,67 mg/ml - siroop - 2,67 mg/ml - codeïne 2.67 mg/ml - opium alkaloids and derivatives
codeinesiroop met eucalyptolsmaak conforma 2,67 mg/ml siroop
conforma sa-nv - codeïne 2,67 mg/ml - siroop - 2,67 mg/ml - codeïne 2.67 mg/ml - opium alkaloids and derivatives